349 related articles for article (PubMed ID: 14569639)
1. Preventing pneumococcal disease. ACIP recommends pneumococcal polysaccharide vaccine for all adults age > or = 65.
Whitney CG
Geriatrics; 2003 Oct; 58(10):20-2, 25. PubMed ID: 14569639
[TBL] [Abstract][Full Text] [Related]
2. Rethinking recommendations for use of pneumococcal vaccines in adults.
Whitney CG; Schaffner W; Butler JC
Clin Infect Dis; 2001 Sep; 33(5):662-75. PubMed ID: 11486289
[TBL] [Abstract][Full Text] [Related]
3. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).
;
MMWR Morb Mortal Wkly Rep; 2010 Sep; 59(34):1102-6. PubMed ID: 20814406
[TBL] [Abstract][Full Text] [Related]
4. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Advisory Committee on Immunization Practices
MMWR Recomm Rep; 2000 Oct; 49(RR-9):1-35. PubMed ID: 11055835
[TBL] [Abstract][Full Text] [Related]
5. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2012 Oct; 61(40):816-9. PubMed ID: 23051612
[TBL] [Abstract][Full Text] [Related]
6. Pneumococcal polysaccharide vaccine. Recommendation of the Immunization Practices Advisory Committee.
Ann Intern Med; 1982 Feb; 96(2):203-5. PubMed ID: 6277218
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of pneumococcal polysaccharide vaccine in older adults.
Jackson LA; Neuzil KM; Yu O; Benson P; Barlow WE; Adams AL; Hanson CA; Mahoney LD; Shay DK; Thompson WW;
N Engl J Med; 2003 May; 348(18):1747-55. PubMed ID: 12724480
[TBL] [Abstract][Full Text] [Related]
8. Higher pneumococcal disease vaccination rates needed to protect more at-risk US adults.
Rehm SJ; Farley MM; File TM; Hall WJ; Hopkins R; Levine OS; Nichol KL; Nuorti P; Zimmerman RK; Schaffner W
Postgrad Med; 2009 Nov; 121(6):101-5. PubMed ID: 19940420
[TBL] [Abstract][Full Text] [Related]
9. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention.
Lynch JP; Zhanel GG
Semin Respir Crit Care Med; 2009 Apr; 30(2):189-209. PubMed ID: 19296419
[TBL] [Abstract][Full Text] [Related]
10. Adults with invasive pneumococcal disease: missed opportunities for vaccination.
Kyaw MH; Greene CM; Schaffner W; Ray SM; Shapiro M; Barrett NL; Gershman K; Craig AS; Roberson A; Zell ER; Schuchat A; Bennett NM; Whitney CG;
Am J Prev Med; 2006 Oct; 31(4):286-92. PubMed ID: 16979452
[TBL] [Abstract][Full Text] [Related]
11. Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001-2003.
Greene CM; Kyaw MH; Ray SM; Schaffner W; Lynfield R; Barrett NL; Long C; Gershman K; Pilishvili T; Roberson A; Zell ER; Whitney CG; Bennett NM;
Clin Infect Dis; 2006 Jul; 43(2):141-50. PubMed ID: 16779739
[TBL] [Abstract][Full Text] [Related]
12. Education does pay off: pneumococcal vaccine screening and administration in hospitalized adult patients with pneumonia.
Kruspe R; Lillis R; Daberkow DW; Blais CM; Wilbright W; Gupta S; Gould CA; Sun T; Martinez JA; deBoisblanc B; Ladabaum U; Sanders CV; Lopez FA
J La State Med Soc; 2003; 155(6):325-31. PubMed ID: 14750752
[TBL] [Abstract][Full Text] [Related]
13. Pneumococcal vaccine in the prevention of community-acquired pneumonia: a skeptical view of cost-effectiveness.
Simberkoff MS
Semin Respir Infect; 1993 Dec; 8(4):294-9. PubMed ID: 7938926
[TBL] [Abstract][Full Text] [Related]
14. Time for changes in pneumococcal vaccination of adults?
Overman MC
J Am Osteopath Assoc; 2011 Oct; 111(10 Suppl 6):S19-22. PubMed ID: 22086890
[TBL] [Abstract][Full Text] [Related]
15. Increasing pneumococcal vaccination rates among patients of a National Health-Care Alliance--United States, 1993.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1995 Oct; 44(40):741-4. PubMed ID: 7565554
[TBL] [Abstract][Full Text] [Related]
16. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2005 Sep; 54(36):893-7. PubMed ID: 16163262
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine co-administered with routine vaccine combinations.
Adam D; Fehnle K
Vaccine; 2008 Nov; 26(47):5944-51. PubMed ID: 18801402
[TBL] [Abstract][Full Text] [Related]
18. Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine--United States, 1997-2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2009 Jan; 58(1):1-4. PubMed ID: 19145219
[TBL] [Abstract][Full Text] [Related]
19. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2012 Jun; 61(21):394-5. PubMed ID: 22647745
[TBL] [Abstract][Full Text] [Related]
20. Pneumococcal vaccination in the prevention of community-acquired pneumonia: an optimistic view of cost-effectiveness.
Fedson DS
Semin Respir Infect; 1993 Dec; 8(4):285-93. PubMed ID: 7938925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
